Prognostic value of symptoms, bioparameters and phenotype in patients with COVID-19

Authors

Keywords:

COVID-19, Prognostic factors, Symptoms, Bioparameters, Phenotype, Mortality.

Abstract

Among the symptoms of COVID-19 prognostic value are fever, diarrhea, abdominal pain and dyspnea; while the signs can be pulmonary rales, arterial hypotension, hypoxemia, tachypnea and tachycardia. Also the patient's phenotype may be associated with the risk of death.The work is proposed as an objectiveto evaluate the ability of a model to predict the risk of dying in patients with COVID-19, based on clinical manifestations and phenotypes. An analytical observational cohort study was carried out in patients with COVID-19 treated in the services of the hospital "COVID-19", of the general provincial hospital Carlos Manuel de Céspedes of Bayamo municipality, Granma province, from January 1, 2020 to December 31, 2022.The Cox proportional model proved that the variable with the highest association with the risk of dying from covid-19 was classifying in phenotype 5 (Hazard ratio= 8.09;  95 % CI= 3.45-18.92; p = 0.000) followed by classifying in phenotype 4 (Hazard ratio= 2.21; 95 % CI= 1.84-5.79; p = 0.008) and blood pressure ≤ 90/60 mmHg (Hazard ratio= 1.49;  95 % CI= 1.26-2.63; p =0.008). None of the symptoms showed independent association with the prognosis of death due to COVID-19.The association with the risk of dying from COVID-19 and phenotype 4 and 5 was demonstrated, as well as the bioparameters of tissue hypoperfusion. The model obtained can be used to predict the evolution of individuals with the aforementioned disease.

Downloads

Download data is not yet available.

Author Biographies

Liannys Lidia Naranjo Flores, Hospital General Provincial Carlos Manuel de Céspedes, Bayamo, Granma

Especialista de primer grado en Medicina Interna. Profesor Instructor

Julio César González Aguilera, Hospital General Provincial Carlos Manuel de Céspedes, Bayamo, Granma

Doctor en Ciencias Médicas. Especialista de segundo grado en Medicina Interna y Medicina Intensiva y Emergencias. Profesor e Investigador Titular.

Adrián Gamboa Suárez, Hospital General Provincial Carlos Manuel de Céspedes, Bayamo, Granma

Especialista de primer grado en Medicina Interna. Profesor Instructor.

Luis Ángel Lara Sosa, Hospital General Provincial Carlos Manuel de Céspedes, Bayamo, Granma

RESIDENTE DE TERCER AÑO DE MEDICINA INTERNA

Yennis Ladrón de Guevara Álvarez, Hospital General Provincial Carlos Manuel de Céspedes, Bayamo, Granma

Licenciada en Enfermería. Profesor Instructor

References

1. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020 Aug; 81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021

2. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020; 369:m1328. doi: 10.1136/bmj.m1328.

3. Lee Y, Min P, Lee S, Kim SW. Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients. J Korean Med Sci. 2020; 35(18):e174. doi: 10.3346/jkms.2020.35.e174.

4. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020; 7(7):CD013665. doi: 10.1002/14651858.CD013665.

5. Lusczek ER, Ingraham NE, Karam BS, Proper J, Siegel L, Helgeson ES, et al. Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles. PLoS One. 2021; 16(3):e0248956. doi: 10.1371/journal.pone.0248956

6. Azoulay E, Zafrani L, Mirouse A, Lengliné E, Darmon M, Chevret S. Clinical phenotypes of critically ill COVID-19 patients. Intensive Care Med. 2020; 46(8): 1651-2. doi: 10.1007/s00134-020-06120-4.

7. Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS ONE. 2020;15(3): e0230548. https://doi.org/10.1371/journal.pone.0230548.

8. Tomidokoro D, Asai Y, Hayakawa K, Kutsuna S, Terada M, Sugiura W, et al. Comparison of the clinical characteristics and outcomes of Japanese patients with COVID-19 treated in primary, secondary, and tertiary care facilities. J Infect Chemother. 2023; 29:302-8. https://doi.org/10.1016/j.jiac.2022.12.003.

9. Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). ClinExp Pediatr. 2020; 63(4):119-24. Doi: 10.3345/cep.2020.00493.

10. Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med. 2000; 19(1): 113-32. doi: 10.1002/(sici)1097-0258(20000115)19:1<113::aid-sim245>3.0.co;2-o.

11. de León-Vidal M, Elias-Sierra R, Rodríguez-Pérez ZI, Estevan-Soto JA, Bordelois-Abdo MS. Marcadores de oxigenación para la predicción de mortalidad por neumonía causada por la COVID-19. Rev Inf Cient. 2022; 101(6): e3886.

12. Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoSOne. 2020; 15(11): e0241955. doi: 10.1371/journal.pone.0241955.

13. López Reyes R, Oscullo G, Jiménez D, Cano I, García Ortega A. Riesgo trombótico y COVID-19: revisión de la evidencia actual para una mejor aproximación diagnóstica y terapéutica. Arch Bronconeumol. 2021; 57(S1): 55-64.

14. Nobel YR, Phipps M, Zucker J, Lebwohl B, Wang TC, Sobieszczyk ME, et al. Gastrointestinal symptoms and COVID-19: case-control study from the United States. Gastroenterology. 2020; 159(1): 373–5. doi:10.1053/j.gastro.2020.04.017

15. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, Spijker R, et al. Diagnosis of SARS-CoV-2 infection and COVID-19: accuracy of signs and symptoms; molecular, antigen, and antibody tests; and routine laboratory markers. Cochrane Database Syst Rev. 2020; 2020(4): CD013596. doi:10.1002/14651858.CD013596

16. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021; 76(2):428-55. doi: 10.1111/all.14657

17. Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One. 2021 Mar; 16(3): e0247461. doi: 10.1371/journal.pone.0247461

18. Hou W, Zhang W, Jin R, Liang L, Xu B, Hu Z. Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study. Infect Dis (Lond). 2020 Jul; 52(7): 498-505. doi: 10.1080/23744235.2020.1759817.

19. Belvis R. Headaches During COVID-19: My Clinical Case and Review of the Literature. Headache. 2020; 60(7): 1422-6. doi: 10.1111/head.13841

20. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 683-90. doi: 10.1001/jamaneurol.2020.1127

21. Russell B, Moss C, Papa S, Irshad S, Ross P, Spicer J, et al. Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London. Front Oncol. 2020; 10: 1279. doi: 10.3389/fonc.2020.01279

22. Naranjo-Flores L, Álvarez-Aliaga A, González-Aguilera JC, Suárez-Quesada A, Quesada-Vázquez AJ. Asociación de la comorbilidad y biomarcadores con el riesgo de morir por COVID-19 en pacientes graves. MULTIMED. 2023; 27: e2911.

23. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J. 2021 Jan 7; 42(2): 206. doi: 10.1093/eurheartj/ehaa190

24. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1; 5(7): 802-10. doi: 10.1001/jamacardio.2020.0950

25. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al.

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020; 323(16): 1612-4. doi: 10.1001/jama.2020.4326.

26. Obregón-Santos Á, Adolfo-Prohias J, Pérez-Barreda A, Vila-García E. Insuficiencia cardíaca aguda en época de COVID-19. Revista Cubana de Cardiología y Cirugía Cardiovascular. [Internet]. 2020 [citado 16/05/2023]; 26(2). Disponible en: file:///C:/Users/Marlenis/Downloads/995-7141-1-PB.pdf.

27. Salinas-Botrán A, Sanz-Cánovas J, Pérez-Somarriba J, Pérez-Belmonte LM, CobosPalacios L, Rubio-Rivas M, et al. Características clínicas y factores de riesgo de mortalidad al ingreso en pacientes con insuficiencia cardíaca hospitalizados por COVID-19 en España. Rev Clin Esp. 2022; 222(5): 255-65. DOI: 10.1016/j.rce.2021.06.004.

28. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. 2021 [citado 13 /09/2023]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK570371/

29. Zhang R, Ouyang H, Fu L, Wang S, Han J, Huang K, et al. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. Eur Radiol. 2020; 30(8): 4417-26. doi: 10.1007/s00330-020-06854-1

30. Casas-Rojo JM, Antón-Santos JM, Millán-Núñez-Cortés J, Lumbreras-Bermejo C, Ramos-Rincón JM, Roy-Vallejo E, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. Rev ClinEsp (Barc). 2020; 220(8): 480-94. doi: 10.1016/j.rce.2020.07.003.

31. Burke RM, Killerby ME, Newton S, Ashworth CE, Berns AL, Brennan S, et al. Symptom Profiles of a Convenience Sample of Patients with COVID-19 - United States, January-April 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(28): 904-8. doi: 10.15585/mmwr.mm6928a2

Downloads

Published

2023-09-13

How to Cite

1.
Naranjo Flores LL, González Aguilera JC, Gamboa Suárez A, Lara Sosa L Ángel, Ladrón de Guevara Álvarez Y. Prognostic value of symptoms, bioparameters and phenotype in patients with COVID-19. RM [Internet]. 2023 Sep. 13 [cited 2025 Jun. 1];27:e2925. Available from: https://revmultimed.sld.cu/index.php/mtm/article/view/2925

Issue

Vol. 27 (2023): Publicación continua

Section

ARTÍCULOS ORIGINALES

License

Avisos de derechos de autor propuestos por Creative Commons

1. Política propuesta para revistas que ofrecen acceso abierto

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).